Exelon rivastigmine acetylcholinesterase inhibitor: Phase III data; marketed in EU, U.S. NDA submitted

Novartis published in the International Journal of Geriatric Psychopharmacology

Read the full 98 word article

How to gain access

Continue reading with a
two-week free trial.